*Predictive value of Diffusion weighted MRI in patients with HNSCC treated by (chemo)radiotherapy (PREDICT study)*

Recruiting

• Conditions: head and neck squamous cell carcinoma; throat cancer; 10027655; 10046304

• Registration Number: NL-OMON56355
• Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 11 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 120

Inclusion Criteria

-Squamous cell carcinoma
-T2, T3 or T4 oral cavity or pharynx
-T3 or T4 larynx
-Technically resectable
-Scheduled for primary (chemo)radiation with curative intent
-*Informed consent* signed by patient

Exclusion Criteria

-Age < 18 years
-Pregnancy
-Patients unsuited for MRI examination as defined in the protocols of the
Radiology department.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The primary endpoint is the predictive value of DW-MRI and ctDNA after the<br /><br>start of radiotherapy based on a single scan during treatment.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>ADC level and tumor volume pretreatment;<br /><br>Change in ADC levels, ctDNA and gross tumor volume prior to, during and after<br /><br>therapy;<br /><br>The optimal time point for MRI scanning during treatment in order to predict<br /><br>treatment outcome.</p><br>